Stent geeks are being treated to a complex analysis in the Lancet that concludes Johnson & Johnson’s drug-coated Cypher device is “clinically better” than arch-rival Boston Scientific’s Taxus model.
But the technique used to reach that conclusion appears almost as controversial as the heart devices themselves. Researchers led by a group at Switzerland’s Institute of Social and Preventive Medicine in Bern, combined data from 38 studies involving more than 18,000 patients. It’s another so-called meta-analysis that combs data from previous clinical tests for fresh insights. (Look back just a few months at the hubbub triggered by cardiologist Steven Nissen’s meta-analysis of trials of GlaxoSmithKline’s Avandia.)
No comments:
Post a Comment